Core Insights - GENFIT SA reported an EPS of -$0.24, significantly below the expected $1.19, indicating financial challenges [1][6] - The company's revenue was approximately $40.3 million, falling short of the estimated $114.7 million, reflecting difficulties in meeting market expectations [1][6] Financial Position - As of June 30, 2025, GENFIT had cash and cash equivalents of €107.5 million, excluding a €26.5 million milestone payment received in July 2025 [2] - The revenues for the first half of 2025 were €33.5 million, supported by the milestone payment, with strong sales of Iqirvo noted in the primary biliary cholangitis (PBC) market [3] Strategic Decisions - The company has discontinued the VS-01 program, extending its cash runway beyond 2028, which provides flexibility for future business initiatives [4] - GENFIT is advancing its pipeline, with Phase 1b data for GNS561 in cholangiocarcinoma expected by the end of 2025, alongside safety data for G1090N in ACLF [4] Valuation Metrics - The price-to-sales ratio is 2.53, and the enterprise value to sales ratio is 2.25, reflecting the company's market valuation [5] - A debt-to-equity ratio of 0.90 indicates a balanced use of debt and equity, while a current ratio of 1.23 suggests reasonable liquidity [5]

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries€33.5 million in revenues, including the €26.5 million milestone invoiced in May 2025Strong 1H25 sales trajectory reported by Ipsen for Iqirvo® in PBC in July, followed by U.S. market exit of key competitor in SeptemberFollowing discontinuation of the VS-01 pro ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder). GENFIT’s decision follows the occurrence of a peritonitis case reported as Seri ...